Literature DB >> 18298385

Biological characteristics of cancers involving the serosal cavities.

Ben Davidson1.   

Abstract

The presence of cancer cells in effusions within the serosal (peritoneal, pleural, and pericardial) cavities is a clinical manifestation of advanced-stage cancer and is associated with poor survival. Tumor cells in effusions most frequently originate from primary carcinomas of the ovary, breast, and lung, and from malignant mesothelioma, a native tumor of this anatomic site. Unlike the majority of solid tumors, particularly at the primary site, cancer cells in effusions are not amenable to surgical removal and failure in their eradication is one of the main causes of treatment failure. In recent years, we have studied the biological characteristics of ovarian carcinoma, breast carcinoma, and malignant mesothelioma cells in effusions and compared it to their counterparts in primary tumors and solid metastases. Our data show that a large number of cancer-associated molecules, including cell adhesion proteins, proteolytic enzymes, growth factor receptors, signaling molecules, and transcription factors, are differentially expressed along tumor progression and have a different prognostic value, depending on the organ sampled. In ovarian carcinoma, several of these molecules are differentially expressed in primary diagnosis (prechemotherapy) and disease recurrence (postchemotherapy) specimens, reflecting the effect of disease progression and chemotherapy, and have different prognostic significance as function of disease progression. The findings presented in this review underscore the need to take into consideration the unique biology of cancer cells in effusions if patient-tailored molecular therapy is to become a successful treatment modality in these malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18298385     DOI: 10.1615/critrevoncog.v13.i3.10

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  12 in total

1.  PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.

Authors:  Y Yuan; H P Dong; D A Nymoen; J M Nesland; C Wu; B Davidson
Journal:  Cytopathology       Date:  2011-02       Impact factor: 2.073

2.  HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Authors:  Thea Eline Hetland; Arild Holth; Janne Kærn; Vivi Ann Flørenes; Claes G Tropé; Ben Davidson
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

3.  Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.

Authors:  Kjersti Brusegard; Helene Tuft Stavnes; Dag André Nymoen; Kjersti Flatmark; Claes G Trope; Ben Davidson
Journal:  Virchows Arch       Date:  2012-01-17       Impact factor: 4.064

4.  Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.

Authors:  Jean-Pierre Gillet; Junbai Wang; Anna Maria Calcagno; Lisa J Green; Sudhir Varma; Mari Bunkholt Elstrand; Claes G Trope; Suresh V Ambudkar; Ben Davidson; Michael M Gottesman
Journal:  Mol Pharm       Date:  2011-07-15       Impact factor: 4.939

5.  Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells.

Authors:  Maciej Malecki; Robert Proczka; Joanna Chorostowska-Wynimko; Paweł Swoboda; Anna Delbani; Jan Pachecka
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

6.  Tenascin-X is a novel diagnostic marker of malignant mesothelioma.

Authors:  Yuan Yuan; Dag André Nymoen; Helene Tuft Stavnes; Anne Katrine Rosnes; Ola Bjørang; Chuanyue Wu; Jahn M Nesland; Ben Davidson
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

7.  Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status.

Authors:  Annika J Bock; Helene Tuft Stavnes; Janne Kærn; Aasmund Berner; Anne Cathrine Staff; Ben Davidson
Journal:  Tumour Biol       Date:  2011-02-26

8.  Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.

Authors:  Ben Davidson; Helene Tuft Stavnes; Arild Holth; Xu Chen; Yanqin Yang; Ie-Ming Shih; Tian-Li Wang
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

9.  MR imaging features of peritoneal adenomatoid mesothelioma: a case report.

Authors:  Cynthia Maria Coelho Lins; Jorge Elias; Adilson Ferreira Cunha; Valdair Francisco Muglia; Carlos Ribeiro Monteiro; Fábio V Valeri; Omar Feres
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

10.  Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure.

Authors:  Ilana Weiss; Claes G Trope; Reuven Reich; Ben Davidson
Journal:  Int J Mol Sci       Date:  2012-10-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.